Bradley R Groveman
Overview
Explore the profile of Bradley R Groveman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foliaki S, Groveman B, Dews E, Williams K, El Soufi H, Schwarz B, et al.
Acta Neuropathol Commun
. 2024 Dec;
12(1):192.
PMID: 39707496
Misfolding of normal prion protein (PrP) to pathological isoforms (prions) causes prion diseases (PrDs) with clinical manifestations including cognitive decline and mood-related behavioral changes. Cognition and mood are linked to...
2.
Groveman B, Race B, Hughson A, Haigh C
PLoS One
. 2024 Nov;
19(11):e0312837.
PMID: 39509453
Prion diseases are transmissible, fatal neurologic diseases of mammals caused by the accumulation of mis-folded, disease associated prion protein (PrPd). Creutzfeldt-Jakob Disease (CJD) is the most common human prion disease...
3.
Groveman B, Williams K, Race B, Foliaki S, Thomas T, Hughson A, et al.
Emerg Infect Dis
. 2024 May;
30(6):1193-1202.
PMID: 38781931
Chronic wasting disease (CWD) is a cervid prion disease with unknown zoonotic potential that might pose a risk to humans who are exposed. To assess the potential of CWD to...
4.
Orru C, Groveman B, Hughson A, Barrio T, Isiofia K, Race B, et al.
PLoS Pathog
. 2024 Apr;
20(4):e1012175.
PMID: 38640117
Prions or prion-like aggregates such as those composed of PrP, α-synuclein, and tau are key features of proteinopathies such as prion, Parkinson's and Alzheimer's diseases, respectively. Their presence on solid...
5.
Williams K, Foliaki S, Race B, Smith A, Thomas T, Groveman B, et al.
Stem Cell Res Ther
. 2023 Dec;
14(1):348.
PMID: 38049877
Background: Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, is a fatal neurodegenerative disease with currently no treatment options. Stem cell therapy for neurodegenerative diseases is emerging as...
6.
Groveman B, Schwarz B, Bohrnsen E, Foliaki S, Carroll J, Wood A, et al.
J Biol Chem
. 2023 Oct;
299(11):105319.
PMID: 37802314
Mis-folding of the prion protein (PrP) is known to cause neurodegenerative disease; however, the native function of this protein remains poorly defined. PrP has been linked with many cellular functions,...
7.
Baune C, Groveman B, Hughson A, Thomas T, Twardoski B, Priola S, et al.
PLoS One
. 2023 Aug;
18(8):e0290325.
PMID: 37616303
Prion diseases are transmissible, fatal neurologic diseases that include Creutzfeldt-Jakob Disease (CJD) in humans, chronic wasting disease (CWD) in cervids, bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep....
8.
Vascellari S, Orru C, Groveman B, Parveen S, Fenu G, Pisano G, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011456.
PMID: 37390080
Abnormal deposition of α-synuclein is a key feature and biomarker of Parkinson's disease. α-Synuclein aggregates can propagate themselves by a prion-like seeding-based mechanism within and between tissues and are hypothesized...
9.
Foliaki S, Wood A, Williams K, Smith A, Walters R, Baune C, et al.
Redox Biol
. 2023 May;
63:102733.
PMID: 37172395
Cellular prion protein (PrP) protects neurons against oxidative stress damage. This role is lost upon its misfolding into insoluble prions in prion diseases, and correlated with cytoskeletal breakdown and neurophysiological...
10.
Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease
Mok T, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T, et al.
Brain
. 2023 Mar;
146(6):2570-2583.
PMID: 36975162
Human prion diseases are remarkable for long incubation times followed typically by rapid clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are remarkably useful in the clinical phase, but...